Evidence map›Paper›PMID 41228367›Full record

ArticleCancers2025

Revisiting p53 Immunohistochemical Staining and Its Prognostic Implications in Advanced EGFR-Mutated Lung Adenocarcinoma.

Feng-Che Kuan, Shun-Fu Chang, Yao-Ren Yang, Yu-Ying Wu, Fen-Fen Chen, Kam-Fai Lee, Chen-Lin Chi, Meng-Hung Lin, Chung-Sheng Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Feng-Che KuanGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan 333323, Taiwan.
Shun-Fu ChangDepartment of Medical Research and Development, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.ORCID 0000-0002-2276-7785
Yao-Ren YangDivision of Hematology and Oncology, Department of Medicine, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.
Yu-Ying WuDivision of Hematology and Oncology, Department of Medicine, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.ORCID 0000-0003-3858-4112
Fen-Fen ChenDepartment of Pathology, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan.
Kam-Fai LeeDepartment of Pathology, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.
Chen-Lin ChiDepartment of Pathology, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.
Meng-Hung LinHealth Information and Epidemiology Laboratory, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan.ORCID 0000-0002-8594-3360
Chung-Sheng ShiGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan 333323, Taiwan.ORCID 0000-0002-5548-7675

Funding

Chiayi Chang Gung Memorial Hospital CMRPG6L0302
6 · The paper itself

Abstract

BACKGROUND/

objectives

methodsPatients with advanced/metastatic EGFR-mutated lung adenocarcinoma treated with first-line tyrosine kinase inhibitors were retrospectively enrolled. Sanger sequencing was performed to detect

resultsThe study involved 83 patients with adequate tumor samples for

conclusionsTumor p53 immunostaining (≥50%) was associated with better OS, especially in patients with

Indexed as

cancerepidermal growth factor receptorKaplan-Meier analysislung adenocarcinomap53 proteinTP53 mutation

Identifiers

PMID41228367
PMCPMC12608574

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.